Non-invasive health assessment assay in sturgeon broodstock

在加拿大，有三种鲟鱼在养殖中用于鱼子酱。在过去的十年里， 行业呈指数级增长，Target海洋孵化场(BC)和Acadian鲟鱼和鱼子酱 自2011年以来，鱼子酱产量增加了60%，Breviro Caviar Inc. 2013年，通过250万美元的扩张，其产量翻了两番(Financial Post，2013)。现在，俄罗斯人， 自2014年以来，西伯利亚鲟鱼和白鲸在北卡罗来纳州和佛罗里达州销售。健康， 然而，与陆生鱼类不同的是，养殖鱼类对这些行业的盈利和可持续性至关重要。 牛，野生动物，甚至伴随的动物产业，鱼类养殖，特别是鲟鱼养殖缺乏任何 感染、炎症和/或应激的诊断测试。因为鲟鱼寿命很长，所以晚熟的鱼 并不是每年都产卵，它们的大多数种群都遭受着极端的剥削和濒危， 繁殖力强的亲鱼很稀有，而且非常有价值。这为非侵入性、快速 健康检查。在其他物种中，急性时相蛋白(APP)评估因以下原因变得更有价值 它们的灵敏度和预测功能。血清淀粉样蛋白A和结合珠蛋白(HP)高度保守 已知在大西洋鲟鱼中对细菌/内毒素的反应具有类似的动力学 脊椎动物。Somru BioScience Inc.是一家新兴的生物技术公司，致力于开发 突破性抗体技术，用于研究、诊断和治疗应用。Somru想要 启动这一项目，将公司打造为水产养殖业的高质量生物检测供应商。 Somru开发定制抗体并产生高质量的试剂，使药物开发和 对抗体试剂进行符合目的的验证。这项研究的目标是：确定 鲟鱼APP保守区(SAA、Hp、SRT)的研究 并测定细菌攻击下大西洋鲟鱼血液中APP的动态变化。

There are three species of sturgeon grown in culture for caviar within Canada. Over the past decade this industry has grown exponentially, and both Target Marine Hatcheries (BC) and Acadian Sturgeon and Caviar Inc. (NB),have experienced increased caviar production by >60% since 2011, and Breviro Caviar Inc. (NB) quadrupled its production in 2013 through a $2.5 million expansion (Financial Post, 2013). Now, Russian, Siberian and Beluga sturgeon are being marketed out of North Carolina and Florida, since 2014. Healthy, cultured fish are crucial to the profitability and sustainability of these industries, however, unlike terrestrial cattle, wildlife or even companion animal industries, fish culture and specifically sturgeon culture lacks any diagnostic test for infection, inflammation and or stress. As sturgeons are long lived, late maturing fish that do not spawn every year, and most of their populations suffer from extreme exploitation and endangerment, highly fecund broodstock are rare and extremely valuable. This creates an important niche for non-invasive, rapid health screening. In other species, acute phase protein (APP) assessments have become more valuable due to their sensitivity and predictive function. Serum amyloid A and haptoglobin (Hp) are highly conserved specifically and are known to respond in Atlantic sturgeon to bacteria/LPS with similar kinetics to higher vertebrates. Somru BioScience Inc. is an emerging biotechnology company dedicated to developing breakthrough antibody technology for research, diagnostic and therapeutic applications. Somru would like to initiate this project to establish the company as a high quality bioassay provider for the aquaculture industry. Somru develops custom antibodies and generate quality reagents that enable drug development and can perform fit-for purpose validations for antibody reagents. The objectives of this research are to: Determine conserved regions of APP (SAA, Hp, Srt) in sturgeon species, develop polyclonal antibodies to sturgeon APP and determine kinetics of APP in blood of Atlantic sturgeon under bacterial challenge.